Results 121 to 130 of about 208,828 (307)
The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. [PDF]
, 2002 The yeast silent information regulator (Sir)2 protein links cellular metabolism and transcriptional silencing through its nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylase activity.Frye, Roy A, North, Brian J, Ott, Melanie, Schwer, Bjorn, Verdin, Eric +4 morecore Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo [PDF]
, 2013 Targeted drugs have significantly improved the therapeutic options for advanced renal cell carcinoma (RCC). However, resistance often develops, negating the benefit of these agents.Bartsch, Georg, Blaheta, Roman A., Haferkamp, Axel, Jüngel, Eva, Makarević, Jasmina, Nelson, Karen, Tsaur, Igor +6 morecore +2 more sourcesData from The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade
, 2023 Victoria El‐Khoury, Etienne Moussay, Bassam Janji, Valérie Palissot, Nasséra Aouali, Nicolaas H. C. Brons, Kris Van Moer, Sandrine Pierson, Eric Van Dyck, Guy Berchem +9 moreopenalex +1 more sourceSupplementary Data from JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
, 2023 Janine Arts, Peter King, Ann Marin, Wim Floren, Ann Belin, Lut Janssen, Isabelle Pilatte, Bruno Roux, Laurence Decrane, Ron Gilissen, Ian D. Hickson, Veronique Vreys, Eugene L. Cox, Kees Bol, Willem Talloen, Ilse Goris, Luc Andries, Marc Du Jardin, Michel Janicot, Martin Pagé, Kristof Van Emelen, Patrick Angibaud +21 moreopenalex +1 more sourceTargeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Nature Communications, 2018 Alteration of the epigenetic landscape has been implicated in several disease processes, where targeting histone modifiers may have therapeutic applications.Jay H. Kalin, Muzhou Wu, Andrea V. Gomez, Yun Song, Jayanta Das, Dawn Hayward, Nkosi Adejola, Mingxuan Wu, Izabela Panova, Hye Jin Chung, Edward Kim, Holly J. Roberts, Justin M. Roberts, Polina Prusevich, Jeliazko R. Jeliazkov, Shourya S. Roy Burman, Louise Fairall, Charles Milano, Abdulkerim Eroglu, Charlotte M. Proby, Albena T. Dinkova-Kostova, Wayne W. Hancock, Jeffrey J. Gray, James E. Bradner, Sergio Valente, Antonello Mai, Nicole M. Anders, Michelle A. Rudek, Yong Hu, Byungwoo Ryu, John W. R. Schwabe, Andrea Mattevi, Rhoda M. Alani, Philip A. Cole +33 moredoaj +1 more sourceSupplementary Figures 1-6 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
, 2023 Leo Kretzner, Anna Scuto, Pamela M. Dino, Claudia Kowolik, Jun Wu, Patrick Ventura, Richard Jove, Stephen J. Forman, Yun Yen, Mark Kirschbaum +9 moreopenalex +2 more sourcesHistone deacetylases and their inhibitors in kidney diseases
Molecular TherapyHistone deacetylases (HDACs) have emerged as key regulators in the pathogenesis of various kidney diseases. This review explores recent advancements in HDAC research, focusing on their role in kidney development and their critical involvement in the progression of chronic kidney disease (CKD), acute kidney injury (AKI), autosomal dominant polycystic ...Yue Zheng, Tie-Ning Zhang, Peng-Hui Hao, Ni Yang, Yue Du +4 moreopenaire +2 more sources
